You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 4
  • 297 Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study

Article info

Article menu

Download PDFPDF

Ovarian cancer
297 Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study
Free

Authors

Citation

Gonzalez-Martin A, Chung HC, Saada-Bouzid E, et al
297 Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study
International Journal of Gynecologic Cancer 2020;30:A64-A65.

Publication history

  • First published December 4, 2020.
Online issue publication 
February 04, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.